Last updated: May 8, 2026
Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (1:13-cv-01874): Litigation Summary and Patent/ANDA Analysis
Core outcome (as reflected in the public docket record): The case is docketed as 1:13-cv-01874 in federal court and involves Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. The matter is in the ANDA/patent-litigation universe, consistent with the parties and the standard Hatch-Waxman caption structure. No complete merits disposition (e.g., final judgment dates, claim construction holdings, infringement findings, or settlement terms) is available in the information provided in this prompt. Under strict operating constraints, this prevents a complete and accurate patent-by-patent litigation analysis.
What is the case and what procedural posture does the docket indicate?
The only actionable identifiers provided are:
- Case name: Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc.
- Federal case number: 1:13-cv-01874
- Docket year: 2013 (implied by the case number prefix “1:13-”)
This identifies the proceeding at the correct docket level, but it does not provide:
- the drug name
- the asserted patent numbers
- the ANDA application number
- the claimed Orange Book listed patents
- the court (district)
- the key dates (complaint filing date, answer, Markman schedule, trial date, final judgment, appellate status)
- the specific claims and the district court rulings that would support an evidence-based analysis
What patents and Orange Book issues are implicated?
A litigation-quality analysis requires the following inputs to map the lawsuit to the Orange Book and the ANDA structure:
- asserted patent list (e.g., US patents, reissues, method-of-use vs composition)
- each patent’s expiration and regulatory protection status at the relevant time
- the ANDA’s paragraph certifications (Paragraph I/II/III/IV) for each listed patent
- the specific “Hatch-Waxman” theory per asserted patent (invalidity defenses, non-infringement positions, carve-outs, design-around, etc.)
Those details are not present in the prompt content, so no accurate patent-by-patent litigation analysis can be produced.
How does the case typically map to Hatch-Waxman mechanics (without asserting facts not in the record provided)?
In ANDA patent litigation, the litigation workflow usually proceeds through:
- complaint asserting infringement of one or more Orange Book listed patents
- alleged ANDA-based infringement tied to the ANDA label and formulation
- court case management leading to claim construction (“Markman”)
- summary judgment and/or trial decisions on infringement and validity
- resolution by judgment or settlement with entry of a stipulated judgment
But without the docket’s specific events for this case, applying this workflow to Millennium v. Zydus would risk factual misstatement.
What is the infringement and validity posture?
A Bloomberg-grade litigation analysis normally includes:
- court findings on:
- claim construction (key terms)
- infringement (literal vs doctrine of equivalents, product vs method)
- validity (anticipation/obviousness; §102/§103; written description/enablement; indefiniteness; prosecution history estoppel)
- a timeline of rulings and outcomes
No such ruling data is available in the prompt. Under strict constraints, the analysis cannot specify infringement/validity posture, claim scope outcomes, or invalidity rationales.
What does the litigation outcome likely mean for timelines and market entry (without overstating)?
The commercial impact of an ANDA litigation outcome depends on:
- whether the court entered:
- an injunction (and scope)
- a finding of non-infringement
- a finding of invalidity
- whether the parties settled and the terms:
- launch date
- “design-around” commitments
- exclusivity or payment provisions (if any)
No court disposition or settlement information is provided, so the market-entry analysis cannot be made without fabricating facts.
Case records that would anchor an evidence-grade summary (not available in provided content)
A complete litigation summary for 1:13-cv-01874 would typically cite:
- complaint and answer filings
- claim construction orders
- summary judgment opinions
- final judgment / stipulated dismissal
- any Federal Circuit appellate opinions
None of those documents are included in the prompt, so a complete summary is not possible.
Key Takeaways
- The matter is identified as Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:13-cv-01874.
- The prompt does not provide the core litigation artifacts needed to produce an accurate patent and merits analysis (asserted patents, ANDA certifications, claim construction, infringement/validity rulings, and case disposition).
- Under the stated constraints, a litigation summary with patent-by-patent legal conclusions cannot be completed from the information provided.
FAQs
1) What court and judge handled 1:13-cv-01874?
Not provided in the prompt.
2) Which drug and Orange Book patents were asserted by Millennium?
Not provided in the prompt.
3) What was Zydus’s ANDA paragraph certification posture?
Not provided in the prompt.
4) Did the court issue Markman claim construction or summary judgment decisions?
Not provided in the prompt.
5) What was the final case disposition (judgment vs settlement) and any effect on launch?
Not provided in the prompt.
References
[1] Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:13-cv-01874 (case caption/identifier as provided in prompt).
